GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (FRA:RDDA) » Definitions » Cyclically Adjusted PS Ratio

Dr Reddy's Laboratories (FRA:RDDA) Cyclically Adjusted PS Ratio : 4.06 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Dr Reddy's Laboratories Cyclically Adjusted PS Ratio?

As of today (2024-05-22), Dr Reddy's Laboratories's current share price is €62.50. Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €15.39. Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio for today is 4.06.

The historical rank and industry rank for Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:RDDA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.27   Med: 3.94   Max: 5.89
Current: 4.22

During the past years, Dr Reddy's Laboratories's highest Cyclically Adjusted PS Ratio was 5.89. The lowest was 2.27. And the median was 3.94.

FRA:RDDA's Cyclically Adjusted PS Ratio is ranked worse than
75.67% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.135 vs FRA:RDDA: 4.22

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dr Reddy's Laboratories's adjusted revenue per share data for the three months ended in Mar. 2024 was €4.706. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €15.39 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dr Reddy's Laboratories Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Cyclically Adjusted PS Ratio Chart

Dr Reddy's Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 4.13 3.64 3.61 4.48

Dr Reddy's Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.61 3.90 4.16 4.25 4.48

Competitive Comparison of Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio falls into.



Dr Reddy's Laboratories Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=62.50/15.39
=4.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dr Reddy's Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.706/153.0345*153.0345
=4.706

Current CPI (Mar. 2024) = 153.0345.

Dr Reddy's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.539 94.103 4.129
201409 2.676 96.780 4.231
201412 2.908 96.780 4.598
201503 3.346 97.163 5.270
201506 3.069 99.841 4.704
201509 3.140 101.753 4.722
201512 3.202 102.901 4.762
201603 2.947 102.518 4.399
201606 2.518 105.961 3.637
201609 2.883 105.961 4.164
201612 3.122 105.196 4.542
201703 3.044 105.196 4.428
201706 2.758 107.109 3.941
201709 2.778 109.021 3.900
201712 3.013 109.404 4.215
201803 2.651 109.786 3.695
201806 2.828 111.317 3.888
201809 2.709 115.142 3.601
201812 2.876 115.142 3.822
201903 3.081 118.202 3.989
201906 2.952 120.880 3.737
201909 3.683 123.175 4.576
201912 3.345 126.235 4.055
202003 3.238 124.705 3.974
202006 3.118 127.000 3.757
202009 3.399 130.118 3.998
202012 3.308 130.889 3.868
202103 3.280 131.771 3.809
202106 3.339 134.084 3.811
202109 4.000 135.847 4.506
202112 3.755 138.161 4.159
202203 3.895 138.822 4.294
202206 3.798 142.347 4.083
202209 4.770 144.661 5.046
202212 4.657 145.763 4.889
202303 4.295 146.865 4.475
202306 4.542 150.280 4.625
202309 4.655 151.492 4.702
202312 4.765 152.924 4.768
202403 4.706 153.035 4.706

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dr Reddy's Laboratories  (FRA:RDDA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Dr Reddy's Laboratories Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Reddy's Laboratories (FRA:RDDA) Business Description

Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (FRA:RDDA) Headlines

No Headlines